RUNX1	B:C0665119
-	I:C0665119
ETO	I:C0665119
Leukemia	O
AML1	O
-	I:C0665119
ETO	I:C0665119
leukemia	O
is	O
the	O
most	O
common	O
cytogenetic	O
subtype	O
of	O
acute	O
myeloid	I:C0023440
leukemia	I:C0023440
,	O
defined	O
by	O
the	O
presence	O
of	O
t(	O
8;21	I:C3897139
)	I:C3897139
.	O

RUNX1	O
-	I:C0665119
ETO	I:C0665119
Leukemia	B:C0023418
AML1	O
-	I:C0665119
ETO	I:C0665119
leukemia	O
is	O
the	O
most	O
common	O
cytogenetic	O
subtype	O
of	O
acute	O
myeloid	I:C0023440
leukemia	I:C0023440
,	O
defined	O
by	O
the	O
presence	O
of	O
t(	O
8;21	I:C3897139
)	I:C3897139
.	O

RUNX1	O
-	I:C0665119
ETO	I:C0665119
Leukemia	O
AML1	B:C0665119
-	I:C0665119
ETO	I:C0665119
leukemia	O
is	O
the	O
most	O
common	O
cytogenetic	O
subtype	O
of	O
acute	O
myeloid	I:C0023440
leukemia	I:C0023440
,	O
defined	O
by	O
the	O
presence	O
of	O
t(	O
8;21	I:C3897139
)	I:C3897139
.	O

RUNX1	O
-	I:C0665119
ETO	I:C0665119
Leukemia	O
AML1	O
-	I:C0665119
ETO	I:C0665119
leukemia	B:C0023418
is	O
the	O
most	O
common	O
cytogenetic	O
subtype	O
of	O
acute	O
myeloid	I:C0023440
leukemia	I:C0023440
,	O
defined	O
by	O
the	O
presence	O
of	O
t(	O
8;21	I:C3897139
)	I:C3897139
.	O

RUNX1	O
-	I:C0665119
ETO	I:C0665119
Leukemia	O
AML1	O
-	I:C0665119
ETO	I:C0665119
leukemia	O
is	O
the	O
most	O
common	O
cytogenetic	B:C0000768
subtype	O
of	O
acute	O
myeloid	I:C0023440
leukemia	I:C0023440
,	O
defined	O
by	O
the	O
presence	O
of	O
t(	O
8;21	I:C3897139
)	I:C3897139
.	O

RUNX1	O
-	I:C0665119
ETO	I:C0665119
Leukemia	O
AML1	O
-	I:C0665119
ETO	I:C0665119
leukemia	O
is	O
the	O
most	O
common	O
cytogenetic	O
subtype	B:C0449560
of	O
acute	O
myeloid	I:C0023440
leukemia	I:C0023440
,	O
defined	O
by	O
the	O
presence	O
of	O
t(	O
8;21	I:C3897139
)	I:C3897139
.	O

RUNX1	O
-	I:C0665119
ETO	I:C0665119
Leukemia	O
AML1	O
-	I:C0665119
ETO	I:C0665119
leukemia	O
is	O
the	O
most	O
common	O
cytogenetic	O
subtype	O
of	O
acute	B:C0023440
myeloid	I:C0023440
leukemia	I:C0023440
,	O
defined	O
by	O
the	O
presence	O
of	O
t(	O
8;21	I:C3897139
)	I:C3897139
.	O

RUNX1	O
-	I:C0665119
ETO	I:C0665119
Leukemia	O
AML1	O
-	I:C0665119
ETO	I:C0665119
leukemia	O
is	O
the	O
most	O
common	O
cytogenetic	O
subtype	O
of	O
acute	O
myeloid	I:C0023440
leukemia	I:C0023440
,	O
defined	O
by	O
the	O
presence	O
of	O
t(	B:C3897139
8;21	I:C3897139
)	I:C3897139
.	O

Remarkable	O
progress	O
has	O
been	O
achieved	O
in	O
understanding	O
the	O
molecular	O
pathogenesis	B:C0699748
of	O
AML1	O
-	I:C0665119
ETO	I:C0665119
leukemia	O
.	O

Remarkable	O
progress	O
has	O
been	O
achieved	O
in	O
understanding	O
the	O
molecular	O
pathogenesis	O
of	O
AML1	B:C0665119
-	I:C0665119
ETO	I:C0665119
leukemia	O
.	O

Remarkable	O
progress	O
has	O
been	O
achieved	O
in	O
understanding	O
the	O
molecular	O
pathogenesis	O
of	O
AML1	O
-	I:C0665119
ETO	I:C0665119
leukemia	B:C0023418
.	O

Proteomic	B:C0872252
surveies	O
have	O
shown	O
that	O
AML	O
-	I:C1332085
ETO	I:C1332085
forms	O
a	O
stable	O
complex	O
with	O
several	O
transcription	O
factors	I:C0040648
,	O
including	O
E	O
proteins	O
.	O

Proteomic	O
surveies	B:C0038951
have	O
shown	O
that	O
AML	O
-	I:C1332085
ETO	I:C1332085
forms	O
a	O
stable	O
complex	O
with	O
several	O
transcription	O
factors	I:C0040648
,	O
including	O
E	O
proteins	O
.	O

Proteomic	O
surveies	O
have	O
shown	O
that	O
AML	B:C1332085
-	I:C1332085
ETO	I:C1332085
forms	O
a	O
stable	O
complex	O
with	O
several	O
transcription	O
factors	I:C0040648
,	O
including	O
E	O
proteins	O
.	O

Proteomic	O
surveies	O
have	O
shown	O
that	O
AML	O
-	I:C1332085
ETO	I:C1332085
forms	O
a	O
stable	O
complex	B:C1704241
with	O
several	O
transcription	O
factors	I:C0040648
,	O
including	O
E	O
proteins	O
.	O

Proteomic	O
surveies	O
have	O
shown	O
that	O
AML	O
-	I:C1332085
ETO	I:C1332085
forms	O
a	O
stable	O
complex	O
with	O
several	O
transcription	B:C0040648
factors	I:C0040648
,	O
including	O
E	O
proteins	O
.	O

Genome	B:C3178810
-	I:C3178810
wide	I:C3178810
transcriptome	I:C3178810
and	O
ChIP	O
-	I:C3831111
seq	I:C3831111
analyses	O
have	O
revealed	O
the	O
genes	O
directly	O
regulated	O
by	O
AML1	O
-	I:C0665119
ETO	I:C0665119
,	O
such	O
as	O
CEBPA	O
.	O

Genome	O
-	I:C3178810
wide	I:C3178810
transcriptome	I:C3178810
and	O
ChIP	B:C3831111
-	I:C3831111
seq	I:C3831111
analyses	O
have	O
revealed	O
the	O
genes	O
directly	O
regulated	O
by	O
AML1	O
-	I:C0665119
ETO	I:C0665119
,	O
such	O
as	O
CEBPA	O
.	O

Genome	O
-	I:C3178810
wide	I:C3178810
transcriptome	I:C3178810
and	O
ChIP	O
-	I:C3831111
seq	I:C3831111
analyses	B:C0936012
have	O
revealed	O
the	O
genes	O
directly	O
regulated	O
by	O
AML1	O
-	I:C0665119
ETO	I:C0665119
,	O
such	O
as	O
CEBPA	O
.	O

Genome	O
-	I:C3178810
wide	I:C3178810
transcriptome	I:C3178810
and	O
ChIP	O
-	I:C3831111
seq	I:C3831111
analyses	O
have	O
revealed	O
the	O
genes	B:C0017337
directly	O
regulated	O
by	O
AML1	O
-	I:C0665119
ETO	I:C0665119
,	O
such	O
as	O
CEBPA	O
.	O

Genome	O
-	I:C3178810
wide	I:C3178810
transcriptome	I:C3178810
and	O
ChIP	O
-	I:C3831111
seq	I:C3831111
analyses	O
have	O
revealed	O
the	O
genes	O
directly	O
regulated	O
by	O
AML1	B:C0665119
-	I:C0665119
ETO	I:C0665119
,	O
such	O
as	O
CEBPA	O
.	O

Genome	O
-	I:C3178810
wide	I:C3178810
transcriptome	I:C3178810
and	O
ChIP	O
-	I:C3831111
seq	I:C3831111
analyses	O
have	O
revealed	O
the	O
genes	O
directly	O
regulated	O
by	O
AML1	O
-	I:C0665119
ETO	I:C0665119
,	O
such	O
as	O
CEBPA	B:C0378310
.	O

Several	O
lines	O
of	O
evidence	O
suggest	O
that	O
AML1	B:C0665119
-	I:C0665119
ETO	I:C0665119
suppresses	O
endogenous	O
DNA	O
repair	I:C0012899
in	O
cells	O
to	O
promote	O
mutagenesis	O
,	O
which	O
facilitates	O
acquisition	O
of	O
cooperating	O
secondary	O
events	O
.	O

Several	O
lines	O
of	O
evidence	O
suggest	O
that	O
AML1	O
-	I:C0665119
ETO	I:C0665119
suppresses	O
endogenous	O
DNA	B:C0012899
repair	I:C0012899
in	O
cells	O
to	O
promote	O
mutagenesis	O
,	O
which	O
facilitates	O
acquisition	O
of	O
cooperating	O
secondary	O
events	O
.	O

Several	O
lines	O
of	O
evidence	O
suggest	O
that	O
AML1	O
-	I:C0665119
ETO	I:C0665119
suppresses	O
endogenous	O
DNA	O
repair	I:C0012899
in	O
cells	B:C0007634
to	O
promote	O
mutagenesis	O
,	O
which	O
facilitates	O
acquisition	O
of	O
cooperating	O
secondary	O
events	O
.	O

Several	O
lines	O
of	O
evidence	O
suggest	O
that	O
AML1	O
-	I:C0665119
ETO	I:C0665119
suppresses	O
endogenous	O
DNA	O
repair	I:C0012899
in	O
cells	O
to	O
promote	O
mutagenesis	B:C0079866
,	O
which	O
facilitates	O
acquisition	O
of	O
cooperating	O
secondary	O
events	O
.	O

Furthermore	O
,	O
it	O
has	O
become	O
increasingly	O
apparent	O
that	O
a	O
delicate	O
balance	B:C0014653
of	O
AML1	O
-	I:C0665119
ETO	I:C0665119
and	O
native	O
AML1	O
is	O
important	O
to	O
sustain	O
the	O
malignant	O
cell	I:C0334227
phenotype	O
.	O

Furthermore	O
,	O
it	O
has	O
become	O
increasingly	O
apparent	O
that	O
a	O
delicate	O
balance	O
of	O
AML1	B:C0665119
-	I:C0665119
ETO	I:C0665119
and	O
native	O
AML1	O
is	O
important	O
to	O
sustain	O
the	O
malignant	O
cell	I:C0334227
phenotype	O
.	O

Furthermore	O
,	O
it	O
has	O
become	O
increasingly	O
apparent	O
that	O
a	O
delicate	O
balance	O
of	O
AML1	O
-	I:C0665119
ETO	I:C0665119
and	O
native	O
AML1	B:C0215508
is	O
important	O
to	O
sustain	O
the	O
malignant	O
cell	I:C0334227
phenotype	O
.	O

Furthermore	O
,	O
it	O
has	O
become	O
increasingly	O
apparent	O
that	O
a	O
delicate	O
balance	O
of	O
AML1	O
-	I:C0665119
ETO	I:C0665119
and	O
native	O
AML1	O
is	O
important	O
to	O
sustain	O
the	O
malignant	B:C0334227
cell	I:C0334227
phenotype	O
.	O

Translation	O
of	O
these	O
findings	B:C0243095
into	O
the	O
clinical	O
setting	O
is	O
just	O
beginning	O
.	O

